Micell Technologies
7516 Precision Drive
Raleigh
North Carolina
27617
United States
Tel: 919-313-2102
Fax: 919-313-2103
Website: http://www.micell.com/
Email: info@micell.com
44 articles about Micell Technologies
-
Micell Technologies Announces Expanded Patent Estate
3/20/2018
- Issued Key Patents Significantly Strengthen Company's Proprietary Rights in Surface Modification and Controlled Drug Delivery -
-
Micell Technologies' Positive Five-Year Data Published for MiStent in EuroIntervention
1/10/2018
The goal of the two trials was to evaluate long-term clinical results for the MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System..
-
The Lancet Publishes Micell Technologies' Twelve-Month Results for DESSOLVE III Highlighting MiStent Performance in All-Comers Randomized Trial; MiStent Achieved Primary Endpoint vs Xience
12/7/2017
Micell Technologies announced that The Lancet has published data from the DESSOLVE III clinical trial.
-
Micell Technologies Announces MiStent Achieved Primary Endpoint In All-Comers Randomized Clinical Trial Versus Xience
5/16/2017
-
Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial Of MiStent In Japan
11/28/2016
-
Durham's Micell Technologies Nabs $26 Million
11/21/2016
-
Positive Five-Year Clinical Data From Micell Technologies' MiStent Presented At TCT 2016
10/31/2016
-
Micell Technologies Completes Enrollment In OCT Study Designed To Evaluate Superior Performance Of MiStent SES Compared To Xience
3/22/2016
-
Micell Technologies Highlights Data From Published Propensity Analysis Of MiStent SES And Market Standard Xience V Coronary Stent
2/25/2016
-
Micell Technologies Announces Completion Of Enrollment In Mistent Randomized Trial Against Xience
12/10/2015
-
Positive Four-Year Clinical Data From Micell Technologies' MiStent SES Presented At TCT 2015
10/13/2015
-
Micell Technologies Announces Surgical Technologies Approved As MiStent SES Commercial Manufacturer For CE Mark Countries
8/20/2015
-
Micell Technologies Announces First Patient Enrolled In Registration Trial Of Mistent SES In China
7/22/2015
-
Micell Technologies Release: EuroPCR Late-Breaking Clinical Trials: MiStent SES Shows Clinical Superiority Over Market-Leader Xience V In Propensity Analysis At One And Three Years Post-Treatment
5/19/2015
-
Micell Technologies: First Patient Enrolled In All-Comers Randomized Trial Of MiStent Against Xience
3/23/2015
-
Micell Technologies' Mistent SESĀ® Now Commercially Available In Europe
2/4/2015
-
Stentys Expands Product Offering To All Coronary Stent Indications Through Exclusive Agreement With Micell Technologies To Distribute Its Novel Drug-Eluting Stent
11/3/2014
-
Micell Technologies Announces Plans For MiStent SESĀ® Commercial Launch
11/3/2014
-
Micell Technologies Adds To Portfolio Of Intellectual Property Protection
7/9/2014
-
Micell Technologies Announces Positive Long-Term Data from MiStent SES Clinical Studies Presented at EuroPCR 2014
5/23/2014